Parkinson's disease (PD) is a systemic chronic neurological disease with evolving layers of complexity. As a typical pathological manifestation of PD, mitochondrial dysfunction is mainly manifested in abnormal energy metabolism and far excess production of reactive oxygen species (ROS). Though many active ingredients have been proven to reverse mitochondrial dysfunction, the presence of the blood-brain barrier (BBB) act as a huge obstacle for the intracerebral delivery of potential therapeutic compounds. Herein, a novel intranasal delivery nanoplatform based on thermosensitive poly (N-isopropylacrylamide) (PNIPAM) hydrogel and Magnolol (MAG)-containing nanocrystals (MAG-NCs@Gel), was developed through in situ free radical polymerization and self-gelation process. Interestingly, viscoelasticity of the MAG-NCs@Gel was increased due to the temperature of nasal cavity higher than its lower critical solution temperature (LCST), thus prolonging the retention time in the nasal cavity. Notably, the AUC0-t of brain after intranasal administration was almost 27 times higher than that of intravenous administration. Furthermore, intranasal delivery of MAG-NCs@Gel was able to continuously deliver MAG-NCs to cross the BBB into dopaminergic neurons for effectively treating MPTP-induced PD mice. This intranasal delivery nanoplatform showed excellent neuroprotective effect on balancing the level of ROS and ATP in dopaminergic neurons mitochondria, thus reversing the mitochondrial dysfunction, recovering the cerebral glucose metabolism, improving the dopamine levels, and enhancing the behavioral performance of PD mice without side effect to normal organs. These findings considered supporting the idea that intranasal delivery of anti-parkinsonian drugs may represent a breakthrough advancement in the fight against PD. This study was supported by the Guangdong Basic and Applied Basic Research Foundation (2019B1515120043), the Research Fund of University of Macau (File no. MYRG2019-00121-ICMS and MYRG2018-00207-ICMS) and the Science and Technology Development Fund, Macau SAR (File no. 0098/2020/A).